EP1220909A2 - Compositions et methodes therapeutiques utilisant des proteines morphogeniques, des hormones et des recepteurs d'hormones - Google Patents

Compositions et methodes therapeutiques utilisant des proteines morphogeniques, des hormones et des recepteurs d'hormones

Info

Publication number
EP1220909A2
EP1220909A2 EP00965478A EP00965478A EP1220909A2 EP 1220909 A2 EP1220909 A2 EP 1220909A2 EP 00965478 A EP00965478 A EP 00965478A EP 00965478 A EP00965478 A EP 00965478A EP 1220909 A2 EP1220909 A2 EP 1220909A2
Authority
EP
European Patent Office
Prior art keywords
bmp
xaa
hormone
res
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00965478A
Other languages
German (de)
English (en)
Inventor
John C. Lee
Lee-Chuan C. Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of EP1220909A2 publication Critical patent/EP1220909A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La présente invention concerne des dispositifs et des méthodes permettant d'induire la formation tissulaire chez un mammifère, impliquant l'utilisation d'une protéine morphogénique, d'une hormone et d'un récepteur soluble de l'hormone. L'hormone et le récepteur correspondant sont utilisés pour améliorer l'activité inductive tissulaire de la protéine morphogénique.
EP00965478A 1999-09-27 2000-09-27 Compositions et methodes therapeutiques utilisant des proteines morphogeniques, des hormones et des recepteurs d'hormones Ceased EP1220909A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15626199P 1999-09-27 1999-09-27
US156261P 1999-09-27
PCT/US2000/026528 WO2001023563A2 (fr) 1999-09-27 2000-09-27 Compositions et methodes therapeutiques utilisant des proteines morphogeniques, des hormones et des recepteurs d'hormones

Publications (1)

Publication Number Publication Date
EP1220909A2 true EP1220909A2 (fr) 2002-07-10

Family

ID=22558805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965478A Ceased EP1220909A2 (fr) 1999-09-27 2000-09-27 Compositions et methodes therapeutiques utilisant des proteines morphogeniques, des hormones et des recepteurs d'hormones

Country Status (5)

Country Link
EP (1) EP1220909A2 (fr)
JP (1) JP2003510338A (fr)
AU (1) AU773990B2 (fr)
CA (1) CA2385887A1 (fr)
WO (1) WO2001023563A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454630B1 (fr) * 2003-03-04 2010-10-20 The Technology Development Company Ltd. Composition injectable d'insuline avec une action prolongée et procédé de préparation et utilisation
WO2005111069A2 (fr) * 2004-05-11 2005-11-24 Stryker Corporation Proteines morphogeniques et facteurs de stimulation utilises en therapie genique
CA2838490A1 (fr) * 2011-06-10 2012-12-13 Universite Libre De Bruxelles Cibles et agents pour le traitement de la consolidation insuffisante des fractures osseuses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
EP1027059A2 (fr) * 1997-10-27 2000-08-16 Curis, Inc. Amelioration d'activite morphogene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0123563A2 *

Also Published As

Publication number Publication date
WO2001023563A3 (fr) 2001-10-04
CA2385887A1 (fr) 2001-04-05
WO2001023563A2 (fr) 2001-04-05
AU773990B2 (en) 2004-06-10
AU7619100A (en) 2001-04-30
JP2003510338A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
US20070191276A1 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
CA2238277C (fr) Compositions et procedes therapeutiques mettant en oeuvre des proteines morphogeniques et des facteurs de stimulation
US20060111298A1 (en) Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
CA2265508C (fr) Compositions de proteines-16 morphogenetiques osseuses
JP3681069B2 (ja) Ｂｍｐ−１１組成物
AU6267798A (en) Matrix-free osteogenic devices, implants and methods of use thereof
JP2002505851A (ja) 骨形態形成タンパク（ｂｍｐ）−１７およびｂｍｐ−１８の組成物
US20070066525A1 (en) Compositions and therapeutic methods using morphogenic proteins
WO1998051354A2 (fr) Compositions pour osteogenese induite par des agents morphogenetiques
EP2352750B1 (fr) Tampons utilisés pour la régulation du ph des protéines morphogénétiques osseuses
EP1722810A1 (fr) Combinaison de proteines morphogenes ayant des proprietes inductives
AU773990B2 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
AU2001250962A1 (en) Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
US20080293654A1 (en) Therapeutic methods using Smads
WO2003083079A9 (fr) Generation d'os par therapie genique
US20100168029A1 (en) Methods for treating bone tumors
AU763300B2 (en) Bone morphogenetic protein-16 (BMP-16) compositions
JP2005533089A (ja) 靱帯成長および修復のための組成物および方法
US20070122396A1 (en) Morphogenic proteins and stimulatory factors in gene therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020422

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040325

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20071026